Chuck Royce's CYTK Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 124,297 shares of Cytokinetics, Incorporated (CYTK) worth $8.19 M, representing 0.08% of the portfolio. First purchased in 2014-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in CYTK, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 100,083 shares. Largest reduction occurred in Q2 2014, reducing 700,000 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Cytokinetics Incorporated (CYTK) Holding Value Over Time
Track share changes against reported price movement
Quarterly Cytokinetics Incorporated (CYTK) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -20,129 | Reduce 13.94% | 124,297 | $65.91 |
| Q4 2025 | +44,343 | Add 44.31% | 144,426 | $63.54 |
| Q3 2025 | +100,083 | New Buy | 100,083 | $54.96 |
| Q4 2024 | -24,250 | Sold Out | 0 | $0.00 |
| Q3 2024 | +10,000 | Add 70.18% | 24,250 | $52.80 |
| Q1 2024 | +14,250 | New Buy | 14,250 | $70.11 |
| Q2 2014 | -700,000 | Sold Out | 0 | $0.00 |
| Q1 2014 | +700,000 | New Buy | 700,000 | $9.50 |
Chuck Royce's Cytokinetics Incorporated Investment FAQs
Chuck Royce first purchased Cytokinetics, Incorporated (CYTK) in Q1 2014, acquiring 700,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Cytokinetics, Incorporated (CYTK) for 9 quarters since Q1 2014.
Chuck Royce's largest addition to Cytokinetics, Incorporated (CYTK) was in Q1 2014, adding 700,000 shares worth $6.65 M.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 124,297 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $8.19 M.
As of the Q1 2026 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.08% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Cytokinetics, Incorporated (CYTK) was 700,000 shares, as reported at the end of Q1 2014.